Amendments to the Claims:

This listing of claims will replace all prior versions and listings of claims in the application.

Listing of Claims:

1. (Currently Amended) A compound represented by ~~the~~ formula (I):

(I)

wherein R is naphthyl optionally substituted with a halogen atom or indolyl optionally substituted with a halogen atom, W represents a bond or an optionally substituted divalent linear hydrocarbon group, X represents an optionally substituted divalent hydrocarbon group, Y represents -CO-, ring A represents an optionally substituted piperidine ring, Z^1 and Z^3 independently represent a bond, Z^2 represents $-N(R^1)-$ (R^1 represents an optionally substituted hydrocarbon group, an optionally substituted acyl group, an optionally esterified carboxyl group, or an optionally substituted carbamoyl group), ring B represents an optionally substituted imidazole ring, wherein a substituent that the optionally substituted imidazole ring represented by ring B may have may be taken together with R^1 to form an optionally substituted ring, and a represents 2, or a salt thereof.

2-4. (Cancelled)

5. (Original) The compound according to claim 1, wherein W is a bond.

6. (Original) The compound according to claim 1, wherein X is an optionally substituted divalent linear hydrocarbon group.

7-8. (Cancelled)

9. (Original) The compound according to claim 1, wherein the formula:

is the formula:



or

wherein R^2, R^3, R^4, R^5, R^6, R^7, R^8, R^9, R^{10}, R^{11}, R^{12} and R^{13} independently represent a hydrogen atom, an optionally substituted hydrocarbon group, an optionally substituted hydroxyl group, an optionally substituted thiol group, an optionally substituted alkylsulfinyl group, an optionally substituted alkylsulfonyl group, an optionally substituted acyl group, an optionally esterified carboxyl group, an optionally substituted carbamoyl group or an optionally substituted amino group, or R^2 and R^3, R^5 and R^6, R^6 and R^7, R^8 and R^9, R^9 and R^{10}, or R^{11} and R^{12} may be taken together to form an optionally substituted ring.

10. (Original) The compound according to claim 1, wherein the formula:

is the formula:



wherein ring C represents an optionally substituted nitrogen-containing heterocyclic ring, and other symbols are as defined in claim 9.

11. (Previously Presented) The compound according to claim 1, wherein a substituent that the optionally substituted imidazole ring represented by ring B may have and R^1 together do not form a ring.

12. (Cancelled)

13. (Previously Presented) The compound according to claim 1, wherein the formula (I) is the formula (Ia):



(Ia)

wherein ring B' represents an optionally further substituted imidazole ring, Z^{2a} represents N, Z^4 represents an optionally substituted divalent linear hydrocarbon group, and other symbols are as defined in claim 1.

14. (Cancelled)

15. (Original) The compound ac cording to claim 13, wherein Z^3 and Z^4 are independently a divalent linear hydrocarbon group optionally substituted with an oxo group.

16. (Original) The compound according to claim 1, wherein the formula (I) is the formula (Ib):



wherein R^{14} and R^{15} independently represent a hydrogen atom, an optionally substituted hydrocarbon group, an optionally substituted hydroxyl group, an optionally substituted thiol group, an optionally substituted alkylsulfinyl group, an optionally substituted alkylsulfonyl group, an optionally substituted acyl group, an optionally esterified carboxyl group, an optionally substituted carbamoyl group, or an optionally substituted amino group, or R^{14} and R^{15} may be taken together to form an optionally substituted ring, and other symbols are as defined in claim 1 or 13.

17. (Original) The compound according to claim 1, wherein the formula (I) is the formula (Ic):



wherein R^{16} and R^{17} independently represent a hydrogen atom, an optionally substituted hydrocarbon group, an optionally substituted hydroxyl group, an optionally substituted thiol group, an optionally substituted alkylsulfinyl group, an optionally substituted alkylsulfonyl group, an optionally substituted acyl group, an optionally esterified carboxyl group, an optionally substituted carbamoyl group or an optionally substituted amino group, or R^{16} and R^{17} may be taken together to form an optionally substituted ring, and other symbols are as defined in claim 1 or 13.

18. (Original) The compound according to claim 1, wherein the formula (I) is the formula (Id):



(Id)

wherein R^{18} and R^{19} independently represent a hydrogen atom, an optionally substituted hydrocarbon group, an optionally substituted hydroxyl group, an optionally substituted thiol group, an optionally substituted alkylsulfinyl group, an optionally substituted alkylsulfonyl group, an optionally substituted acyl group, an optionally esterified carboxyl group, an optionally substituted carbamoyl group, or an optionally substituted amino group, and other symbols are as defined in claim 1 or 13.

19. (Cancelled)

20. (Currently Amended) A compound selected from the group consisting of
2-(1-{3-[(6-chloro-2-naphthyl)sulfonyl]propanoyl}-4-piperidinyl)-5-methyl-1,2-dihydro-3H-imidazo[1,5-c]imidazol-3-one,
2-(1-{3-[(6-chloro-2-naphthyl)sulfonyl]propanoyl}-4-piperidinyl)-5,7-dimethyl-1,2-dihydro-3H-imidazo[1,5-c]imidazol-3-one,
2-(1-{3-[(5-chloro-1H-indol-2-yl)sulfonyl]propanoyl}-4-piperidinyl)-5-methyl-1,2-dihydro-3H-imidazo[1,5-c]imidazol-3-one,
2-(1-{3-[(6-chloro-2-naphthyl)sulfonyl]propanoyl}-4-piperidinyl)-5-(hydroxymethyl)-1,2-dihydro-3H-imidazo[1,5-c]imidazol-3-one,
2-(1-{(2S)-3-[(6-chloro-2-naphthyl)sulfonyl]-2-hydroxypropanoyl}-4-piperidinyl)-5-(hydroxymethyl)-~~1, 2 dihydro~~1,2-dihydro-3H-imidazo[1,5-c]imidazol-3-one,
[2-(1-{(2S)-3-[(6-chloro-2-naphthyl)sulfonyl]-2-hydroxypropanoyl}-4-piperidinyl)-3-oxo-2,3-dihydro-1H-imidazo[1,5-c]imidazol-5-yl]methyl 1-acetylpiperidine-4-carboxylate,

[2-(1-{(2S)-3-[(6-chloro-2-naphthyl)sulfonyl]-2-hydroxypropanoyl}-4-piperidinyl)-3-oxo-2,3-dihydro-1H-imidazo[1,5-c]imidazol-5-yl]methyl 3-(2-oxo-1-pyrrolidinyl)propionate,
[2-(1-{(2S)-3-[(6-chloro-2-naphthyl)sulfonyl]-2-hydroxypropanoyl}-4-piperidinyl)-3-oxo-2,3-dihydro-1H-imidazo[1,5-c]imidazol-5-yl]methyl (2-oxo-1-pyrrolidinyl)acetate,
[2-(1-{(2S)-3-[(6-chloro-2-naphthyl)sulfonyl]-2-hydroxypropanoyl}-4-piperidinyl)-3-oxo-2,3-dihydro-1H-imidazo[1,5-c]imidazol-5-yl]methyl 4-(acetylamino)butanoate, and
2-(1-{(2S)-3-[(6-chloro-2-naphthyl)sulfonyl]-2-hydroxypropanoyl}-4-piperidinyl)-5,7-dimethyl-1,2-dihydro-3H-imidazo[1,5-c]imidazol-3-one or a salt thereof.

21. (Previously Presented) A pharmaceutical preparation which comprises the compound according to claim 1.

22. (Previously Presented) The pharmaceutical preparation according to claim 21, which has an anticoagulant effect.

23. (Previously Presented) The pharmaceutical preparation according to claim 21, which inhibits an activated blood coagulation factor X.

24. (Currently Amended) The pharmaceutical preparation according to claim 21, which has an effect on preventing or treating[[-]] myocardial infarction, cerebral infarction, deep venous thrombosis, pulmonary thromboembolism or arterioscleroticobliterans.

25. (Previously Presented) The pharmaceutical preparation according to claim 21, which has an effect on preventing or treating economy class syndrome, thromboembolism during or after an operation, or a secondary onset of deep venous thrombosis.

26 - 37. (Cancelled)